Ifosfamide neuropsychiatric toxicity in patients with cancer

Psycho-Oncology

Volumn 16, Issue 10, 2007, Pages 956-960

  Alici Evcimen, Yesne ^a   Breitbart, William S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cancer; Delirium; Ifosfamide; Neuropsychiatric toxicity; Neurotoxicity; Oncology

Indexed keywords

CYTARABINE; ETOPOSIDE; HALOPERIDOL; IFOSFAMIDE; LORAZEPAM; METHYLENE BLUE;

ADULT; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; BURKITT LYMPHOMA; CANCER RADIOTHERAPY; CASE REPORT; CONSULTATION; DELIRIUM; DELUSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG WITHDRAWAL; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; MEDICAL LITERATURE; MENTAL DISEASE; MENTAL HEALTH CARE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PSYCHOSIS; RELIGION; TREATMENT OUTCOME; TREATMENT REFUSAL;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BURKITT LYMPHOMA; DELUSIONS; ENZYME INHIBITORS; FEMALE; HUMANS; IFOSFAMIDE; METHYLENE BLUE; NEUROTOXICITY SYNDROMES; PROGNOSIS; PSYCHOSES, SUBSTANCE-INDUCED;

EID: 35548930699     PISSN: 10579249     EISSN: 10991611     Source Type: Journal    
DOI: 10.1002/pon.1161     Document Type: Article

References (17)

1. Kerbusch T, Kraker J, Keizer H et al. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Drug Dispos 2001;40:41-62.
2. Kerdudo C, Orbach D, Sarradet JL et al. Ifosfamide neurotoxicity: an atypical presentation with psychiatric manifestations. Pediat Blood Cancer 2005;47(1): 100-102.
3. Kupfer A. Prophylaxis and reversal of ifosfamide encephalopathy with methylene blue. Lancet 1994;343:763-764.
4. Patel PN. Methylene blue for management of ifosfamide induced encephalopathy. Ann Pharmacother 2006;40: 299-303.
5. Fleming RA. An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy 1997;17: S146-S154.
6. David KA, Picus J. Evaluating risk factors for the development of ifosfamide encephalopathy. Am J Clin Oncol 2005;28:277-280.
7. Pelgrims J, De Vos F, Van den Brande J et al. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of literature. Br J Cancer 2000; 82:291-294.
8. Nicolao P, Giometto, B. Neurological toxicity of ifosfamide. Oncology 2003;65:S11-S16.
9. Kaijser GP, Beijnen JH, Butt WJM et al. Ifosfamide metabolism and pharmacokinetics (review). Anticancer Res 1994;14:517-532.
10. Hernandez R, Juan O, Alberola V. Ifosfamide induced psychosis. Acta Oncol 2004;43:119-120.
11. DiMaggio JR, Brown R, Baile WF et al. Hallucinations and ifosfamide induced neurotoxicity. Cancer 1994;73: 1509-1514.
12. Loehrer PJ. The history of ifosfamide. Seminars in Oncology 1992;19(6) Suppl 12:2-7.
13. Aeschlimann T, Cerny T, Kupfer A. Inhibition of (mono)amine oxidase activity and prevention of ifosfamide encephalopathy by methylene, blue. Drug Metab Dispos 1996;24:1336-1339.
14. Dufour C, Grill J, Sabouraud P et al. Ifosfamide induced encephalopathy. Arch Pediatr 2006;13:140-145.
15. Donegan S. Novel treatment for the management of ifosfamide neurotoxicity: rationale for the use of methylene blue. J of Oncol, Pharmacy Practice 2001; 6(4):153-165.
16. Verdeguer A, Castel V, Esquembre C et al. Fatal encephalopathy with ifosfamide/mesna. Pediatr Hematol Oncol 1989; 6:383-385.
17. Kasper B, Harter C, Meissner J et al. Prophylactic treatment of known ifosfamide induced encephalopathy for chemotherapy with high dose Ifosfamide. Support Care Cancer 2004;12:205-207.